Use of fractional factorial designs in antiviral drug studies

Quality and Reliability Engineering International

Volumn 29, Issue 2, 2013, Pages 299-304

  Ding, Xianting ^a   Xu, Hongquan ^a   Hopper, Chanelle ^b   Yang, Jian ^c   Ho, Chih Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

composite design; drug combination; experimental design; fractional factorial design; Herpes simplex virus

Indexed keywords

ANTI-VIRAL DRUGS; BIOLOGICAL RESEARCH; CHEMICAL GROUP; COMPLEX INTERACTION; COMPOSITE DESIGNS; DRUG COMBINATIONS; DRUG MOLECULES; ENGINEERING DOMAINS; EXPERIMENTAL DESIGN AND ANALYSIS; FRACTIONAL FACTORIAL DESIGNS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS TYPE 1; ORTHOGONAL ARRAY; RIBAVIRIN; SCIENTIFIC INVESTIGATION;

AMIDES; ANTIBIOTICS; BIOLOGICAL SYSTEMS; DESIGN; DESIGN OF EXPERIMENTS; DRUG DOSAGE; ELECTRICAL ENGINEERING; GLYCOPROTEINS; INDUSTRIAL APPLICATIONS; STATISTICS; VIRUSES;

DRUG INTERACTIONS;

EID: 84874109771     PISSN: 07488017     EISSN: 10991638     Source Type: Journal    
DOI: 10.1002/qre.1308     Document Type: Article

References (26)

1. Box GEP, Hunter WG, Hunter JS,. Statistics for Experimenters (2nd edn). Wiley: New York, 2005.
2. Box GEP, Draper NR,. Response Surfaces, Mixtures, and Ridge Analyses (2nd edn). Wiley: New York, 2007.
3. Montgomery DC,. Design and Analysis of Experiments (7th edn). Wiley: New York, 2009.
4. Myers RH, Montgomery DC, Anderson-Cook CM,. Response Surface Methodology: Process and Product Optimization Using Designed Experiments (3rd edn). Wiley: New York, 2009.
5. Wu CFJ, Hamada M,. Experiments: Planning, Analysis and Parameter Design Optimization (2nd edn). Wiley: New York, 2009.
6. Mee RW,. A Comprehensive Guide to Factorial Two-Level Experimentation. Springer: New York, 2009.
7. McGrath N, Anderson NE, Croxson MC, Powell KF,. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 63 (3): 321-326.
8. Zuckerman RA, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Zuniga R, Magaret AS, Wald A, Corey L, Celum C,. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-e1 levels in HIV-1/HSV-2-Seropositive men: A randomized, double-blind, placebo-controlled crossover trial. Journal of Infectious Diseases 2007; 196 (10): 1500-1508.
9. Malkin JE, Morand P, Malvy D, Ly TD, Chanzy B, de Labareyre C, El Hasnaoui A, Hercberg S,. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sexually Transmitted Infections 2002; 78 (3): 201-203.
10. Scoular A, Norrie J, Gillespie G, Mir N, Carman WF,. Longitudinal study of genital infection by herpes simplex virus type 1 in western Scotland over 15 years. British Medical Journal 2002; 324 (7350): 1366-1367.
11. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE,. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA: The Journal of the American Medical Association 2006; 296 (8): 964-973.
12. Whitley RJ, Lakeman F,. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clinical Infectious Diseases (1995); 20 (2): 414-20.
13. Rong Q, Alexander TS, Koski GK, Rosenthal KS,. Multiple mechanisms for HSV-1 induction of interferon alpha production by peripheral blood mononuclear cells. Archives of Virology 2003; 148 (2): 329-344.
14. Andersen JH, Jenssen H, Gutteberg TJ,. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Research 2003; 58 (3): 209-215.
15. Biswas S, Sukla S, Field HJ,. Drug resistance mutations in HSV-1 UL5 selected using a helicase-primase inhibitor: Frequency and effects on virus growth and pathogenicity. Antiviral Research 2009; 82 (2): A68-A69.
16. Gray R, Wilson D,. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. The New England Journal of Medicine 2010; 362 (18): 1740-1742.
17. De Clercq E,. Antiviral drugs in current clinical use. Journal of Clinical Virology 2004; 30 (2): 115-133.
18. Cheng SW, Wu CFJ,. Factor screening and response surface exploration (with discussion). Statistica Sinica 2001; 11: 553-604.
19. Xu H, Cheng SW, Wu CFJ,. Optimal projective three-level designs for factor screening and interaction detection. Technometrics 2004; 46: 280-292.
20. Morris MD,. A class of three-level experimental designs for response surface modeling. Technometrics 2000; 42: 111-121.
21. Xu H, Phoa FKH, Wong WK,. Recent developments in nonregular fractional factorial designs. Statistics Surveys 2009; 3: 18-46.
22. Velazquez L, Fellous M, Stark GR, Pellegrini S,. A protein tyrosine kinase in the interferon-alpha/beta signaling pathway. Cell 1992; 70 (2): 313-322.
23. Meier V, Burger E, Mihm S, Saile B, Ramadori G,. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: Possible explanation for therapeutic efficacy in patients with chronic HCV infection. Journal of Medical Virology 2003; 69 (1): 50-58.
24. Colby BM, Shaw JE, Elion GB, Pagano JS,. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. Journal of Virology 1980; 34 (2): 560-568.
25. Sainz B, Halford WP,. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. Journal of Virology 2002 76 (22): 11541-11550.
26. Terzano C, Petroianni A, Ricci A,. Herpes simplex pneumonia: Combination therapy with oral acyclovir and aerosolized ribavirin in an immunocompetent patient. Current Therapeutic Research, Clinical and Experimental 2004; 65 (1): 90-96.